Wednesday, December 8, 2021

SARS-CoV-2

Evidence points to natural origin of Covid, not lab-leak: Scientists

The team, which includes Australian Nobel laureate Professor Peter Doherty, also has scientists from the UK, the US, China, Canada, New Zealand. The study was released on open-access repository Zenodo

Hetero’s phase 3 trial results of Molnupiravir shows fewer hospital admissions

Hyderabad-based pharma company has approached the Drug Controller General of India to seek Emergency Use Authorization for the investigational drug in India

Third wave of Covid-19 may just be a ripple: Study

If there is a SARS-CoV-2 mutant that has the ability to escape immunity, then the size of the third wave could be significant, suggests the study

Phase 3 trial data shows Covaxin to be 77.8% effective against Covid-19

Efficacy data also demonstrates 65.2 per cent protection against the SARS-CoV-2, B.1.617.2 Delta variant, the company said in a statement while announcing its phase 3 data analysis.

Covaxin neutralises Alpha, Delta variants: US top body

Covaxin comprises a disabled form of SARS-CoV-2 that cannot replicate but still stimulates the immune system to make antibodies against the virus.

Dr Reddy’s collaborates with four pharma companies for molnupiravir trial

On successful completion of the clinical trial, each company will independently approach the regulatory authorities for approval to manufacture and supply the drug for the treatment of Covid-19 in India

China’s CoronaVac safe for up to 3-year-old: Lancet

China earlier this month, authorised the emergency use of CoronaVac, for children aged between 3 and 17 years.

Pfizer, Moderna Covid shots generate lasting immunity

Even 15 weeks after the first dose, eight of 10 people still had detectable germinal centers containing B cells targeting the virus.

Explained: Delta Plus variant, a new concern

Scientists are worried about the Delta plus variant due to the presence of Beta variant and the features of the Delta variant in it, which can make it more infectious

Virus that causes COVID-19 can find alternate route to infect cells: Study

Now, researchers at Washington University School of Medicine in St. Louis have found that a single mutation gives SARS-CoV-2 the ability to enter cells through another route - one that does not require ACE2.

Covid-19 vaccination: Telangana giving its ‘best shot’

While the new Covid vaccine policy came into effect across the country, TS perhaps remains the only State that has adopted a measured, practical, and logical approach of vaccinating individuals who need them the most

Researchers explore microbial ecosystem in search of drugs to fight SARS-CoV-2

The research was presented at the World Microbe Forum, an online meeting of the American Society for Microbiology (ASM), the Federation of European Microbiological Societies (FEMS), and several other societies that will take place online June 20-24.

Pfizer, Moderna COVID-19 vaccines don’t lower sperm count, study says

The study, published on Thursday in the journal JAMA, recruited 45 healthy male volunteers aged 18 to 50 years scheduled for mRNA COVID-19 vaccination by Pfizer-BioNTech and Moderna.

IISc’s study gives new insights into structure of Covid spike protein

The research team has observed that around 68 per cent of the S-proteins exist in open formation at physiological pH 7.4, but their proportion decreases when the pH is slightly higher (pH 8.0) or lower (pH 6.5).

New Covid-19 variants pose a risk in Telangana

Experts say continued circulation of coronavirus, threat from new emerging variants create possibility

Latest News

- Advertisement -